Amazing work led by the amazing @OncHahn

Prospective @utswcancer trial at SUO evaluating neoadj sbrt prior to nephrectomy. Led by Drs Margulis and Hannan. Presented by Lin Lin. Data shows: -down-staging in 23% -feasibility of surgery -promising RFS -reduced ki67 New option in those difficult IVC thrombus patient?

Great multi-D session about met RCC management @UroOnc , it is about TEAM WORK to manage any met RCC case @montypal @BradMcG04 @ChadTangMD @katy_beckermann @ejasonabel @KidneyCancerDoc @ShapiroDan

1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: https://t.co/q1UwZr8L3i #endRMC #MsaouelLab @MDAndersonNews

Pleased to share the primary endpoint analysis of the LUNAR trial out in @JCO_ASCO https://t.co/AFHiHssZCi. The addition of 177Lu-PNT2002 to SBRT improved PFS and HT-FS over SBRT alone, without a significant increase in toxicity, in men with oligometastatic prostate cancer

It’s quite a unique experience as the only physicist attending the #IKCSNA25 to present the motion management strategies in treating kidney cancer using SBRT and #Unity MR-Linac. It’s a great honor to present in the session with @ChadTangMD @d_shapiro1 @bergsa83

⁦@d_shapiro1⁩ presenting data showing immune cell infiltration associated with better outcomes in localized kidney cancer #ikcsna25 ⁦@wiscurology⁩ ⁦@WiscUroOnc⁩

Last day of @KidneyCancer 2025. Great collaborations including @ASTRO_org with @_ShankarSiva. Looking forward to continuing partnerships in 2026.

Great session at @KidneyCancer meeting on subsequent line therapy moderated by @AlbigesL and @WesleyYipMD with @MdArpita Lisa Henske, Martin Voss, and Anand Swamimath. Specially great discussion about radiation for oligoprogression! But I may be biased 😜

Big thanks to @ChadTangMD @MDAndersonNews on our Planning Committee for his insights on day one of #IKCSNA25! 🙌 Join us this afternoon for Oral Abstract Sessions (2:10–3:10pm MT) followed by our Keynote from Gordon Freeman, PhD @DanaFarberNews (3:10–3:40pm MT)

Great session hosted by the wonderful @shilpa_surasi and @SNM_MI. Thanks for everyone who came out!

Wonderful organizing @SNM_MI prostate cancer symposium on PSMA imaging and therapy with engaging talks from my @MDAndersonNews colleagues @OncHahn @ChadTangMD @ChapinMD

Doing Nashville right, in between sessions @Uromigos.

Bispecifics in ccRCC look like they could be hot as show in @Uromigos. Looking forward to @PavlosMsaouel IVORY study to show us the way @MDAndersonNews

Fascinating look @Uromigos conference at the current ongoing Chinese trials in bladder cancer @ndesai2005

One of the best med oncs and people I know. Should definitely vote for him @PavlosMsaouel @ndesai2005 @_ShankarSiva @OncHahn @SbrtSean @ebludmir @AlexSherryMD @TylerSbrt @DavidHongMD

#IKCSNA25 begins 11/13 and we're excited to see you! Proud to share the best in #kidneycancer research, updates in treatment & care, and the opportunity to connect with the most passionate people in medicine! Travel safe and we'll see you in the Rockies! https://t.co/I3unThrQBk

Grand start of #UromigosLive @Uromigos by @brian_rini @tompowles1 👉major emphasis on early career investigators👇wonderful to have @huntsmancancer fellow @ziremozay win the only golden ticket award👉it’s a global level meeting now👇kudos to the team👏👏@OncoAlert

1/ Our new editorial asks whether MDT for OMD has been too often treated as a one-time upfront intervention. Have we overlooked the value of a comprehensive, longitudinal strategy—combining close surveillance with serial, strategic SABR when needed? 👉 https://t.co/ZQuYUMJaYR

1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers